Cargando…
Enhancement of SMN protein levels in a mouse model of spinal muscular atrophy using novel drug-like compounds
Spinal muscular atrophy (SMA) is a neurodegenerative disease that causes progressive muscle weakness, which primarily targets proximal muscles. About 95% of SMA cases are caused by the loss of both copies of the SMN1 gene. SMN2 is a nearly identical copy of SMN1, which expresses much less functional...
Autores principales: | Cherry, Jonathan J, Osman, Erkan Y, Evans, Matthew C, Choi, Sungwoon, Xing, Xuechao, Cuny, Gregory D, Glicksman, Marcie A, Lorson, Christian L, Androphy, Elliot J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3721476/ https://www.ncbi.nlm.nih.gov/pubmed/23740718 http://dx.doi.org/10.1002/emmm.201202305 |
Ejemplares similares
-
Short-duration splice promoting compound enables a tunable mouse model of spinal muscular atrophy
por: Rietz, Anne, et al.
Publicado: (2020) -
Motor unit recovery following Smn restoration in mouse models of spinal muscular atrophy
por: Comley, Laura H, et al.
Publicado: (2022) -
Intraperitoneal delivery of a novel drug‐like compound improves disease severity in severe and intermediate mouse models of Spinal Muscular Atrophy
por: Osman, E. Y., et al.
Publicado: (2019) -
A transgene carrying an A2G missense mutation in the SMN gene modulates phenotypic severity in mice with severe (type I) spinal muscular atrophy
por: Monani, Umrao R., et al.
Publicado: (2003) -
Therapeutic strategies for spinal muscular atrophy: SMN and beyond
por: Bowerman, Melissa, et al.
Publicado: (2017)